PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.
Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS.
Dahagam C, et al. Among authors: goud a.
Future Cardiol. 2016 Mar;12(2):149-57. doi: 10.2217/fca.15.88. Epub 2016 Feb 25.
Future Cardiol. 2016.
PMID: 26911710
Review.